Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Immunohistochemical expression of GPNMB in TFEB-rearranged and TFEB-amplified renal cell carcinomas

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F26%3AW0000086" target="_blank" >RIV/00064211:_____/26:W0000086 - isvavai.cz</a>

  • Výsledek na webu

    <a href="https://oadoi.org/10.1007/s00428-026-04466-6" target="_blank" >https://oadoi.org/10.1007/s00428-026-04466-6</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1007/s00428-026-04466-6" target="_blank" >10.1007/s00428-026-04466-6</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Immunohistochemical expression of GPNMB in TFEB-rearranged and TFEB-amplified renal cell carcinomas

  • Popis výsledku v původním jazyce

    TFEB-altered renal cell carcinomas (RCCs) display a wide range of morphological features and variable immunohistochemical profiles, often overlapping with other RCC subtypes. This variability poses significant diagnostic challenges. Consequently, there is an ongoing search for reliable ancillary tests that can aid in identifying cases that warrant molecular testing. In this study, we focused on GPNMB immunohistochemistry expression in TFEB-rearranged and TFEB-amplified RCCs. A total of 25 TFEB-altered RCCs, including 16 TFEB-amplified RCCs and nine TFEB-rearranged RCCs, were included in the study. GPNMB immunohistochemistry was positive in all nine TFEB-rearranged RCCs, demonstrating strong, diffuse cytoplasmic staining. In the TFEB-amplified RCC cohort, GPNMB expression was also detected in all 16 tumors; however, the staining pattern differed from that seen in TFEB-rearranged RCCs. Diffuse staining was observed in eight tumors (50%), four of which showed variable staining intensity, while the remaining eight tumors (50%) exhibited focal GPNMB reactivity, with intervening negative areas. GPNMB was therefore positive in all 25/25 (100%) TFEB-altered RCCs by IHC, supporting its potential role as a sensitive screening marker for such RCCs. TFEB-rearranged RCCs typically exhibited strong, diffuse GPNMB immunoreactivity, whereas TFEB-amplified RCCs more often showed patchy or focal staining of lower intensity, interspersed with areas of GPNMB negativity. Variability of staining in TFEB-amplified RCCs underscores the need for cautious interpretation, particularly in limited biopsy specimens, taking into account the morphologic findings and other immunohistochemistry stains, such as Melan A and Cathepsin K.

  • Název v anglickém jazyce

    Immunohistochemical expression of GPNMB in TFEB-rearranged and TFEB-amplified renal cell carcinomas

  • Popis výsledku anglicky

    TFEB-altered renal cell carcinomas (RCCs) display a wide range of morphological features and variable immunohistochemical profiles, often overlapping with other RCC subtypes. This variability poses significant diagnostic challenges. Consequently, there is an ongoing search for reliable ancillary tests that can aid in identifying cases that warrant molecular testing. In this study, we focused on GPNMB immunohistochemistry expression in TFEB-rearranged and TFEB-amplified RCCs. A total of 25 TFEB-altered RCCs, including 16 TFEB-amplified RCCs and nine TFEB-rearranged RCCs, were included in the study. GPNMB immunohistochemistry was positive in all nine TFEB-rearranged RCCs, demonstrating strong, diffuse cytoplasmic staining. In the TFEB-amplified RCC cohort, GPNMB expression was also detected in all 16 tumors; however, the staining pattern differed from that seen in TFEB-rearranged RCCs. Diffuse staining was observed in eight tumors (50%), four of which showed variable staining intensity, while the remaining eight tumors (50%) exhibited focal GPNMB reactivity, with intervening negative areas. GPNMB was therefore positive in all 25/25 (100%) TFEB-altered RCCs by IHC, supporting its potential role as a sensitive screening marker for such RCCs. TFEB-rearranged RCCs typically exhibited strong, diffuse GPNMB immunoreactivity, whereas TFEB-amplified RCCs more often showed patchy or focal staining of lower intensity, interspersed with areas of GPNMB negativity. Variability of staining in TFEB-amplified RCCs underscores the need for cautious interpretation, particularly in limited biopsy specimens, taking into account the morphologic findings and other immunohistochemistry stains, such as Melan A and Cathepsin K.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30109 - Pathology

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2026

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    VIRCHOWS ARCHIV

  • ISSN

    0945-6317

  • e-ISSN

    1432-2307

  • Svazek periodika

    neuveden

  • Číslo periodika v rámci svazku

    18 February 2026

  • Stát vydavatele periodika

    US - Spojené státy americké

  • Počet stran výsledku

    11

  • Strana od-do

    nestrankovano

  • Kód UT WoS článku

    001705999300001

  • EID výsledku v databázi Scopus